Introduction
AD is a complex neurodegenerative disorder, with aging, genetic and environmental factors contributing to its development and progression. The complexity of AD presents substantial challenges for the development of new therapeutic agents. AD is typified by pathological depositions of beta-amyloid peptides and neurofibrillary tangles within the diseased brain (Jiang et al., 2008 ) . It has also been demonstrated to be associated with a significant microglia-mediated inflammatory component, dysregulated lipid homeostasis and regional deficits in glucose metabolism within the brain. AD also shares some common pathophysiologic hallmarks, such as amyloid beta (Abeta), phosphoralation of tau protein, and glycogen synthase kinase-3 with type 2 diabetes mellitus (Li, 2007) , and thus some drugs acting in diabetes to reduce the incidence of the adverse action of these mediators also promise to be useful in the prevention/reduction of Alzheimer's. This is the case for example of the incretin Glucagon-like peptide-1 (GLP-1). In patients with type 2 diabetes GLP-1 increases pancreatic islet beta-cell proliferation and glucosedependent insulin secretion; it lowers blood glucose and food intake. GLP-1 has cAMP coupled receptors within the brain of rodents and humans, thus, suggesting a central role for the endogenous peptide in the regulation of proper neuronal function as it is plasticity, cell survival, neurite outgrowth and protection against excitotoxic cell death and oxidative injury (Perry and Greig, 2002) . Moreover, from experimental studies GLP-1 was shown to reduce endogenous levels of amyloid-beta peptide (Abeta) in mouse brain and to reduce levels of beta-amyloid precursor protein (betaAPP) in neurons (Perry and Greig, 2003) overall these data suggesting that GLP-1 peptide may beneficially affect a number of therapeutic targets associated with AD.
Unfortunately, GLP-1 peptide usually have short half-life in presence of functionally intact endogenous DPP-4 enzymes. These enzymes usually metabolize GLP-1 within minutes of release to inactive metabolites (Drucker, 2003; Hansen et al., 1999) resulting in very short half-life of intact hormone (about 2 minutes) (Drucker, 2003; Vilsboll et al., 2003) with the consequence that the 4 small amounts of active GLP-1 that survive this initial cleavage act on receptor sites producing the proper responses of the peptide (Drucker, 2006; Meier and Nauck, 2004) . By blocking the activity of the endogenous DPP-4 enzymes one would stabilize the levels of the bioactive GLP-1 (Brown et al., 2004; Knecht et al., 2006) and in theory its effects. Based on this contention, and although much remains to be elucidated with regards to the downstream signaling pathways involved in the properties of GLP-1, we have investigated here an alternative strategy to prevent/treat AD. We aimed to increase the bioactivity of endogenous GLP-1 with a chronic orally administered specific DPP-4 inhibitor, and investigate the effects of this continuous activation of the endogenous incretin axis on the deposition of Aß deposits within the brain and deficits in memory-related behavioural paradigms typical of AD.
Among the DPP-4 inhibitors we selected sitagliptin recently approved for the treatment of type 2 diabetes with a glucose-lowering effect best obtained after long-term treatment (Lamont and Drucker, 2008) . Sitagliptin (Januvia®, Merck Pharmaceuticals) is effective in lowering HbA1c, and fasting as well as postprandial glucose in monotherapy and in combination with other oral antidiabetic agents. It stimulates insulin secretion when hyperglycemia is present and inhibits glucagon secretion (Gallwitz, 2007) . Recent studies underline that the continuous administration of des-fluoro-sitagliptin in the food likely achieves optimal GLP-1 control by a potent and sustained 24-h inhibition of DPP-4 activity especially relative to the twice-daily administration of others DPP-4 inhibitors (Lamont and Drucker, 2008; Larsen et al., 2001 , Raun et.al., 2007 with an end-point being the optimal stimulation of incretin axis and incretin activities.
Methods

Animals
The animals used were the double transgenic mice B6.Cg-Tg(APPswe,PSEN1dE9)85Dbo/J from the Jackson Laboratory (Bar Harbor, USA). These transgenic mice express a chimeric (Jankowsky et al., 2004) resembling those observed in the brains of patients with AD. The number of amyloid deposits increases dramatically between the ages of 10 and 12 months, with an accompanying profound inflammatory component being apparent. Mice (B6.Cg-Tg(APPswe,PSEN1dE9)85Dbo/J, and lean littermates; n = 6 per group) of 7 months of age were used for experiments. They were fed with Purina 5002 rodent chow and drinking water. Sitagliptin was dissolved in normal saline for p.o.
administration (Beconi et al., 2007) . Vehicle (saline) and sitagliptin, at three different doses chosen in the therapeutic range of 11 mg/kg likely being 5, 10, 20 mg/kg, were daily administered by gastric gavage in a 100 microliter volume/10 g body weight. On completion of the study (after 12 weeks of drug treatment) mice were killed by cervical dislocation 2 h after their final morning sitagliptin or vehicle administration and the glucose assay repeated.
In a separate set of experiments exendin (9-39) was also tested. It was continuously administered through Alzet micropumps (Alza, Palo Alto, CA) delivering a rate of 2 pmol/kg/min (Cani et al., 2006) or vehicle (0.9% NaCl) for 12 weeks starting at 7 months of age. Animal care and handling was performed according to the local ethics committees.
Tissue preparation
At the time of sacrifice, the mice were transcardially perfused with heparinized sodium chloride (0.9%). The brains were removed and brain regions were dissected from one hemisphere. One hemisphere was placed into an acryl brain block lined up with the interaural line at 0 mm.
Subsequently, coronal slices were cut to obtain cortical, hippocampal, cerebellar and brainstem sections, which were dissected, snap-frozen in liquid nitrogen and stored at -80°C until further 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65   6 analysis. The remaining brain hemisphere was either fixed in 4% paraformaldehyde followed by paraffin embedding according to standard protocols and sectioning for immunohistochemistry.
Immunohistochemistry
Serial sagittal sections of paraffin-embedded brain tissues were cut (7 µm thick, Leica microtome 2155 or Leica Cryostat CM3050S) and mounted (poly-L-lysine-coated slides, Histobond adhesion slides, Marienfeld, Germany). Retrieval of antigen sites, blocking of endogenous peroxidase activity and blocking of non-specific binding sites were performed according to standard protocols.
After washing in phosphate-buffered saline (PBS), sections were incubated overnight at 4°C with primary antibodies. The antibodies used were: (i) rabbit pAb against Aß1-42 (Biosource International, Inc., USA); and anti-β-APP (Santa Cruz); anti-IL-1β (Santa Cruz); anti-nitrotyrosine (Santa Cruz).
For image analysis of brain immunostaining, serial sagittal sections of one brain hemisphere were examined. β-APP, Aß1-42, immunostaining was evaluated on sagittal brain sections of six animals from each group. For each animal, antigens were detected in 10 parallel sections having a defined distance of 70 µm and showing both the hippocampus and brain cortex. In each section, the hippocampus and the frontal cortex were evaluated. The total stained area (real area) and integral staining density (sum of all individual optical densities of each pixel in the area being measured) were determined and given as percentage of stained surface per region. All images were acquired using a standard light and immunofluorescence microscope (Nikon, Eclipse E-800) connected to a digital camera (Sony, model DXC-9100P, Sony, Köln, Germany) and to a PC system with LUCIA imaging software (LUCIA 32G, version 4.11; Laboratory Imaging, Düsseldorf, Germany). For each animal, average values from all sections were determined. 
Brain amyloid assay
The individual hemisphere was homogenized in 6.5 volumes of ice-cold buffer containing 20 mM Tris-HCl (pH 8.5) and a cocktail of proteinase inhibitors (Roche Mannheim, Germany), using a small Potter-type mechanical homogenizer. After centrifugation (135 000 g for 1 h at 4°C), a portion of the supernatant was centrifuged again (200 000 g for 2 h at 4°C) and soluble amyloid peptides were quantified by enzyme-linked immunosorbent assay (ELISA; IBL international, Hamburg, Germany; assay range 1.56-100 pg/ml).
In another set of experiments brain GLP-1 of B6.Cg-Tg(APPswe,PSEN1dE9)85Dbo/J mice was assayed by using a commercially available ELISA kit (Linco Research, St. Charles, MO; 2pM sensitivity).
Statistical analysis
The data shown are the means ± S.D. Statistical comparisons for significance between mice with different treatments were performed using the Student's t test and ANOVA followed by the Tukey post hoc test.
Behavioural testings
Open-field test
This test was applied as previously described (Onozuka et al., 2008) . Briefly, mice were placed into the corner of a wooden box 50 X 50 X 40 cm and allowed to freely explore for 10 min. The floor of the field was divided into 25 identical squares so that the ambulation of animals could be measured.
The ambulation of the mice was measured by counting the number of times that the animals crossed from one square to another. The scorer of the behavioral experiments was blind to treatment group.
Contextual fear conditioning
In the training session, mice were placed into a chamber with metal grids floor. Mice were allowed to freely explore for 2 min, and were given an electric shock (2 s, 0.7 mA) from a metal grid floor at the end of the 2 min. The 2 min/2 s shock paradigm was repeated for a total of two shocks. After the last shock, animals were allowed to explore the context for an additional 1 min prior to removal from the training chamber. The freezing time (seconds), defined as cessation of all but respiratory movement, was measured by observing the animals every 5 min. Baseline freezing was established for the first 2 min of the training session. Freezing time was also recorded during the last 3 min of the training session (training). In the test session performed 24 h after training, mice were placed into the conditioned chamber for 5 min and freezing time was measured manually (test).
Results
Inhibition of DPP-4 does not affect ambulation counts
Since B6.Cg-Tg(APPswe,PSEN1dE9)85Dbo/J mice began to exhibit a number of amyloid deposits at 9 months of age (Jankowsky et al., 2004) , 7 month-old transgenic mice were daily administered sitagliptin for 12 weeks. We carefully monitored the general health of the mice throughout the course of the treatment with sitagliptin and did not observe any adverse changes nor did we observe significant weight changes. After 12 weeks of the daily administration of sitagliptin we first 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65   9 To examine the effects of sitagliptin on learning and memory, we next used the contextual fear conditioning task, in which animals learn to associate a normally innocuous context with an aversive stimulus (Kim et al., 1991 , Atkins et al., 1998 8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 10 from vehicle-and sitagliptin-treated B6.Cg-Tg(APPswe,PSEN1dE9)85Dbo/J mice with antiamyloid beta antibody. At the age of 10 months, B6.Cg-Tg(APPswe,PSEN1dE9)85Dbo/J mice expressed a considerable number of amyloid deposits throughout the cortex and hippocampus.
Since the contextual fear conditioning paradigm has been previously shown to be hippocampaldependent (Logue et al., 1997) , we analyzed the βAPP and Abeta deposition in the hippocampus. Figure 4A and B). It is noteworthy that exendin (9-39) is specific for the GLP-1 receptor and at the rate studied here, no nonspecific effect could be envisioned as previously described with higher rate (Knauf et al., 2005) .
We next analyzed quantity of Abeta with ELISA to investigate the effects of the DPP-4 inhibitor sitagliptin on Abeta levels in the brain. Administration of sitagliptin for 12 weeks significantly decreased levels of Abeta in the brain. As for example the levels of Abeta within the hippocampus was 12±1.6 pg/mg protein in vehicle-treated mice while it was 6.2±1.1 in sitagliptin-(20 mg/kg, Moreover, BACE1 inactivation rescues memory deficits in transgenic mice (Lesnè et al., 2006) , 12 strongly supporting the importance of BACE1 as a therapeutic target in AD. However, recent objectives have been focused on a new strategy based on the reinforcement of the incretin axis by direct stimulation of it with administration of incretins or analogues or indirectly by blocking their degradation with dipeptidyl peptidase-4 inhibitors. The rationale of using these new classes of drugs in AD may resides in the fact that several studies nowadays have ascertained common pathophysiologic hallmarks, such as amyloid beta (Abeta) with type 2 diabetes mellitus (Li et al, 2007) , and have ascertained some diabetic drugs also useful in the prevention/reduction of Alzheimer's. This is the case for example of the incretin GLP-1 or DPP-4 inhibitors.
While many reports are present in literature on the use of the incretin GLP-1 or its analogues in AD, no study has investigated the second possibility that of use DPP-4 inhibitor in order to prevent amyloid deposits within the brain, thus preventing AD progression. DPP-4 is an enzyme that is localized vastly in the endothelium and can also be measured in the blood. DPP-4 cleaves peptides with an N-terminal alanine or proline amino acid residue (Mentlein et al., 1993) . In case of the incretin GLP-1 the two GLP-1 fragments resulting from DPP-4 activity are both biologically inactive; the fragment GLP-1(9-36) amide has even been described as having GLP-1 antagonistic properties in some studies (Knudsen and Pridal, 1996) . DPP-4 inhibition raises intact GLP-1 plasma concentrations to levels observed in the stimulated state after a meal. Further results in support come from mice deficient in DPP-4/CD26. These animals are resistant to STZ-induced diabetes and have elevated circulating plasma concentrations of intact GLP-1 and other incretin hormones (Marguet et al., 2000) .
We report here that long-term treatment with the DPP-4 inhibitor sitagliptin increases the endogenous levels of GLP-1 and reduces the levels of amyloid-beta peptide ( On another note, we show here that DPP-4 inhibition is associated with a reduction of the inflammation and nitrosative stress within the cerebral structures. This is in agreement with many evidence that i) an inflammatory process in the central nervous system is believed to play an important role in the pathway leading to neuronal cell death (Kubis and Janusz, 2008) , and ii)
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